Hepatitis Monthly

Published by: Kowsar

The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease

Raika Jamali 1 , Neda Hatami 2 and Farid Kosari 3 , *
Authors Information
1 Research Development Center, Digestive Disease Research Institute, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
2 Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2016, 16 (5); e37412
  • Published Online: April 20, 2016
  • Article Type: Research Article
  • Received: February 25, 2016
  • Revised: March 7, 2016
  • Accepted: March 18, 2016
  • DOI: 10.5812/hepatmon.37412

To Cite: Jamali R, Hatami N, Kosari F. The Correlation Between Serum Adipokines and Liver Cell Damage in Non-Alcoholic Fatty Liver Disease, Hepat Mon. 2016 ; 16(5):e37412. doi: 10.5812/hepatmon.37412.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11(1): 18-27[PubMed]
  • 2. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon. 2012; 12(10 HCC)[DOI][PubMed]
  • 3. Gatselis NK, Ntaios G, Makaritsis K, Dalekos GN. Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med. 2014; 14(2): 121-31[DOI][PubMed]
  • 4. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006; 91(3): 1081-6[DOI][PubMed]
  • 5. Jamali R. Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. Thrita J Med Sci. 2013; 2(2): 43-51[DOI]
  • 6. Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol. 2011; 55(4): 920-32[DOI][PubMed]
  • 7. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005; 2(6): 273-80[DOI][PubMed]
  • 8. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011; 60(3): 313-26[DOI][PubMed]
  • 9. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94(9): 2467-74[DOI][PubMed]
  • 10. Kukla M, Ciupinska-Kajor M, Kajor M, Wylezol M, Zwirska-Korczala K, Hartleb M, et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol. 2010; 61(3): 147-53[PubMed]
  • 11. Gaddipati R, Sasikala M, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-Mansard M, et al. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010; 9(3): 266-70[PubMed]
  • 12. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008; 27(5): 412-21[DOI][PubMed]
  • 13. de Boer JF, Bahr MJ, Boker KH, Manns MP, Tietge UJ. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2009; 296(2)-201[DOI][PubMed]
  • 14. Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2009; 54(8): 1772-7[DOI][PubMed]
  • 15. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol. 2013; 12(4): 548-55[PubMed]
  • 16. Murad A, Hassan H, Husein H, Ayad A. Serum resistin levels in nonalcoholic fatty liver disease and their relationship to severity of liver disease. J Endocrinol Metabol Diabetes South Africa. 2010; 15(1): 53-5
  • 17. Baranova A, Gowder SJ, Schlauch K, Elariny H, Collantes R, Afendy A, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006; 16(9): 1118-25[DOI][PubMed]
  • 18. Elsayed EY, Mohamed AS, Elal HA, Hamed E. Diagnostic Role Of Resistin In Nonalchoholic Fatty Liver Disease. Group. 2010; 51: 9.6
  • 19. Shen C, Zhao CY, Wang W, Wang YD, Sun H, Cao W. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gasteroenterol. 2014; 14: 39
  • 20. Senates E, Yilmaz Y, Colak Y, Ozturk O, Altunoz ME, Kurt R, et al. Serum levels of hepcidin in patients with biopsy-proven nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2011; 9(4): 287-90[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments